Here are the 424B prospectus supplements from Alaunos Therapeutics, Inc. (TCRT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TCRT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCRT filings page.
Alaunos Therapeutics, Inc. (TCRT) is conducting a primary offering of 380,469 shares of common stock at $1.46 per share and 386,654 pre-funded warrants at $1.459 each, for aggregate gross proceeds of up to $1,120,000.54 on a best-efforts basis under its $50 million shelf.
The pre-funded warrants are immediately exercisable at $0.001 per share and remain outstanding until fully exercised; assuming full exercise, shares outstanding would rise from 2,546,666 to 3,313,789. Estimated net proceeds of about $915,400, after 8% placement fees and expenses, are earmarked for working capital and general corporate purposes.
Alaunos is a preclinical-stage company focused on oral small-molecule obesity drugs and reported a $4.2 million net loss for 2025, with an accumulated deficit of $924.6 million. Its auditors included a going-concern explanatory paragraph, and the company has a Nasdaq stockholders’ equity deficiency notice and a disclosed material weakness in internal controls.